Tebapivat is an investigational pharmaceutical compound and a selective inhibitor of the mitochondrial pyruvate dehydrogenase complex. Currently under development for the treatment of McArdle disease,… Read more
Tebapivat is an investigational pharmaceutical compound and a selective inhibitor of the mitochondrial pyruvate dehydrogenase complex. Currently under development for the treatment of McArdle disease, or glycogen storage disease type V, the drug functions by inhibiting the conversion of pyruvate to acetyl-CoA to help preserve glycogen stores and alleviate symptoms like muscle cramping. To support the rigorous analytical demands of pharmaceutical development, this category includes essential tebapivat reference standards, related impurities, metabolites, and stable isotope labelled compounds. These high-quality materials are critical for accurate impurity profiling, method validation, and routine quality control testing. By providing precise analytical tools, these substances enable researchers and laboratories to ensure the consistency, safety, and regulatory compliance of tebapivat throughout the drug development lifecycle.